Sorafenib and HDAC inhibitors synergize to kill CNS tumor cells

Cancer Biology and Therapy

Volumn 13, Issue 7, 2012, Pages 567-574

  Tang, Yong ^a   Yacoub, Adly ^a   Hamed, Hossein A ^a   Poklepovic, Andrew ^b   Tye, Gary W ^a   Grant, Steven ^b   Dent, Paul ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Glioma; HDAC inhibitor; Sorafenib

Indexed keywords

CASPASE 9; FAS ANTIGEN; FLICE INHIBITORY PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN BCL XL; S6 KINASE; SORAFENIB; VALPROATE SEMISODIUM; VORINOSTAT;

ARTICLE; CANCER CELL CULTURE; CELL KILLING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ENZYME PHOSPHORYLATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; MEDULLOBLASTOMA; PROTEIN EXPRESSION;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CELL LINE, TUMOR; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM NEOPLASMS; DRUG SYNERGISM; HISTONE DEACETYLASE INHIBITORS; HUMANS; PROTEIN KINASE INHIBITORS; PYRIDINES;

EID: 84861142713     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.19771     Document Type: Article

References (14)

1. Squatrito M, Holland EC. DNA damage response and growth factor signaling pathways in gliomagenesis and therapeutic resistance. Cancer Res 2011; 71:5945-9; PMID:21917735; http://dx.doi.org/10.1158/0008-5472.CAN-11-1245.
2. Buonerba C, Di Lorenzo G, Marinelli A, Federico P, Palmieri G, Imbimbo M, et al. A comprehensive outlook on intracerebral therapy of malignant gliomas. Crit Rev Oncol Hematol 2011; 80:54-68; PMID:20888252; http://dx.doi.org/10.1016/ j.critrevonc.2010.09.001.
3. Bonavia R, Inda MM, Cavenee WK, Furnari FB. Heterogeneity maintenance in glioblastoma: a social network. Cancer Res 2011; 71:4055-60; PMID:21628493; http://dx.doi.org/10.1158/0008-5472.CAN-11-0153.
4. Liu KW, Hu B, Cheng SY. Platelet-derived growth factor receptor alpha in glioma: a bad seed. Chin J Cancer 2011; 30:590-602; PMID:21880180; http://dx.doi.org/10.5732/cjc.011.10236.
5. Park MA, Reinehr R, Häussinger D, Voelkel-Johnson C, Ogretmen B, Yacoub A, et al. Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells. Mol Cancer Ther 2010; 9:2220-31; PMID:20682655; http://dx.doi.org/10.1158/1535-7163.MCT-10-0274.
6. Park MA, Mitchell C, Zhang G, Yacoub A, Allegood J, Häussinger D, et al. Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway. Cancer Res 2010; 70:6313-24; PMID:20631069; http://dx.doi.org/10.1158/0008-5472.CAN-10-0999.
7. Reardon DA, Vredenburgh JJ, Desjardins A, Peters K, Gururangan S, Sampson JH, et al. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J Neurooncol 2011; 101:57-66; PMID:20443129; http://dx.doi.org/10.1007/s11060-010-0217-6.
8. Venugopal B, Evans TR. Developing histone deacetylase inhibitors as anti-cancer therapeutics. Curr Med Chem 2011; 18:1658-71; PMID:21428881; http://dx.doi.org/10.2174/092986711795471284.
9. Reikvam H, Ersvaer E, Bruserud O. Heat shock protein 90 - a potential target in the treatment of human acute myelogenous leukemia. Curr Cancer Drug Targets 2009; 9:761-76; PMID:19754360; http://dx.doi.org/10.2174/ 156800909789271486.
10. Zhang G, Park MA, Mitchell C, Hamed H, Rahmani M, Martin AP, et al. Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clin Cancer Res 2008; 14:5385-99; PMID:18765530; http://dx.doi.org/10.1158/1078-0432.CCR-08-0469.
11. Bolaños JP, Medina JM. Effect of valproate on the metabolism of the central nervous system. Life Sci 1997; 60:1933-42; PMID:9180347; http://dx.doi.org/10.1016/S0024-3205(96)00687-X.
12. Pfister SM, Korshunov A, Kool M, Hasselblatt M, Eberhart C, Taylor MD. Molecular diagnostics of CNS embryonal tumors. Acta Neuropathol 2010; 120:553-66; PMID:20882288; http://dx.doi.org/10.1007/s00401-010-0751-5.
13. Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, Rosa E, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci USA 2003; 100:2041-6; PMID:12576549; http://dx.doi.org/10.1073/pnas.0437870100.
14. Agarwal S, Sane R, Ohlfest JR, Elmquist WF. The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J Pharmacol Exp Ther 2011; 336:223-33; PMID:20952483; http://dx.doi.org/10.1124/ jpet.110.175034.